Identification of CD90 as Putative Cancer Stem Cell Marker and Therapeutic Target in Insulinomas.

The long-term prognosis after surgical resection of malignant insulinoma (INS) is poor. Novel adjuvant therapies, specifically targeting cancer stem cells (CSCs), are warranted. Therefore, the goal of this study was to characterize and target putative INS CSCs. Using fluorescence-activated cell sorting, human INS cell line CM and pancreatic carcinoid cell line BON1 were screened for the presence of stem cell-associated markers. CD90, CD166, and GD2 were identified as potential CSC markers. Only CD90(+) INS cells had an increased tumor-initiating potential in athymic nude mice. Anti-CD90 monoclonal antibodies decreased the viability and metastatic potential of injected cells in a zebrafish embryo INS xenograft model. Primary INS stained positive for CD90 by immunohistochemistry, however also intratumoral fibroblasts and vascular endothelium showed positive staining. The results of this study suggest that anti-CD90 monoclonals form a potential novel adjuvant therapeutic modality by targeting either INS cells directly, or by targeting the INS microenvironment.

[1]  C. Chen,et al.  Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer , 2015, Oncotarget.

[2]  D. Hanahan,et al.  A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. , 2015, Cancer discovery.

[3]  M. Beuran,et al.  The epithelial to mesenchymal transition in pancreatic cancer: A systematic review. , 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[4]  P. Kunz.  Carcinoid and neuroendocrine tumors: building on success. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Imran Ullah,et al.  Human mesenchymal stem cells - current trends and future prospective , 2015, Bioscience reports.

[6]  Min Zhang,et al.  Overexpression of CD90 (Thy-1) in Pancreatic Adenocarcinoma Present in the Tumor Microenvironment , 2014, PloS one.

[7]  S. Carr,et al.  A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages , 2014, Nature Cell Biology.

[8]  G. Morahan,et al.  Pancreatic stem cells remain unresolved. , 2014, Stem cells and development.

[9]  M. Büchler,et al.  A Systematic Review of Localization, Surgical Treatment Options, and Outcome of Insulinoma , 2014, Pancreas.

[10]  T. van der Meulen,et al.  Maturation of stem cell-derived beta-cells guided by the expression of urocortin 3. , 2014, The review of diabetic studies : RDS.

[11]  X. Bian,et al.  Identification of CD90 as a marker for lung cancer stem cells in A549 and H446 cell lines. , 2013, Oncology reports.

[12]  L. Tian,et al.  Detection of pancreatic ductal adenocarcinoma in mice by ultrasound imaging of thymocyte differentiation antigen 1. , 2013, Gastroenterology.

[13]  J. Kirpensteijn,et al.  Gene expression profiling of primary canine insulinomas and their metastases. , 2013, Veterinary journal.

[14]  D. Cui,et al.  Epithelial-mesenchymal transition triggers cancer stem cell generation in human thyroid cancer cells. , 2013, International journal of oncology.

[15]  S. Law,et al.  A CD90(+) tumor-initiating cell population with an aggressive signature and metastatic capacity in esophageal cancer. , 2013, Cancer research.

[16]  Y. Ogawa,et al.  Diagnosis and management of insulinoma. , 2013, World journal of gastroenterology.

[17]  M. Sogayar,et al.  Differential expression of CD90 and CD14 stem cell markers in malignant breast cancer cell lines , 2012, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[18]  A. Trumpp,et al.  The evolving concept of cancer and metastasis stem cells , 2012, The Journal of cell biology.

[19]  D. Castellano,et al.  Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist? , 2012, Cancer and Metastasis Reviews.

[20]  T. Gress,et al.  Epithelial-Mesenchymal Transition Is a Critical Step in Tumorgenesis of Pancreatic Neuroendocrine Tumors , 2012, Cancers.

[21]  Y. Liang,et al.  Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype , 2012, Oncogene.

[22]  F. DiMeco,et al.  CD90 is Identified as a Candidate Marker for Cancer Stem Cells in Primary High-Grade Gliomas Using Tissue Microarrays* , 2011, Molecular & Cellular Proteomics.

[23]  Gaetano Rocco,et al.  Epithelial to Mesenchymal Transition by TGFβ-1 Induction Increases Stemness Characteristics in Primary Non Small Cell Lung Cancer Cell Line , 2011, PloS one.

[24]  Jane E. Visvader,et al.  Cells of origin in cancer , 2011, Nature.

[25]  K. Honke,et al.  Anomalous expression of Thy1 (CD90) in B-cell lymphoma cells and proliferation inhibition by anti-Thy1 antibody treatment. , 2010, Biochemical and biophysical research communications.

[26]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[27]  J. Boujaoudé,et al.  Occult sporadic insulinoma: localization and surgical strategy. , 2008, World journal of gastroenterology.

[28]  S. Fan,et al.  Significance of CD90+ cancer stem cells in human liver cancer. , 2008, Cancer cell.

[29]  G. Camussi,et al.  Isolation and Characterization of a Stem Cell Population from Adult Human Liver , 2006, Stem cells.

[30]  H. Tsai,et al.  TEL-AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia , 2006, Proceedings of the National Academy of Sciences.

[31]  L. Penning,et al.  Development and evaluation of canine reference genes for accurate quantification of gene expression. , 2006, Analytical biochemistry.

[32]  J. Hagood,et al.  Thy‐1 as a regulator of cell‐cell and cell‐matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  J. Simon,et al.  Interaction of human Thy-1 (CD 90) with the integrin αvβ3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium , 2005, Oncogene.

[34]  T. Hunt,et al.  Bone Marrow Contribution to Tumor-Associated Myofibroblasts and Fibroblasts , 2004, Cancer Research.

[35]  B. Weinstein,et al.  In vivo imaging of embryonic vascular development using transgenic zebrafish. , 2002, Developmental biology.

[36]  H. Denk,et al.  Insulinoma of the pancreas with insular–ductular differentiation in its liver metastasis – indication of a common stem-cell origin of the exocrine and endocrine components , 2001, Virchows Archiv.

[37]  A. Saalbach,et al.  Detection of human soluble Thy-1 in serum by ELISA , 1999, Cell and Tissue Research.

[38]  P. Pozzilli,et al.  Beta-cell gene expression and functional characterisation of the human insulinoma cell line CM. , 1999, The Journal of endocrinology.

[39]  T. Tsuruo,et al.  A novel anti‐Thy‐1 (CD90) monoclonal antibody induces apoptosis in mouse malignant T‐lymphoma cells in spite of inducing bcl‐2 expression , 1996, International journal of cancer.

[40]  B. Evers,et al.  The Human Carcinoid Cell Line, BON , 1994 .

[41]  J. Rastad,et al.  Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes , 1992, World Journal of Surgery.

[42]  M. Vidal,et al.  Tissue‐specific control elements of the Thy‐1 gene. , 1990, The EMBO journal.

[43]  M. Ma,et al.  Up-regulation of thy-1 promotes invasion and metastasis of hepatocarcinomas. , 2012, Asian Pacific journal of cancer prevention : APJCP.